Used primarily in cancer research, this compound acts as a checkpoint kinase 1 (CHK1) inhibitor. It enhances the effectiveness of DNA-damaging agents, such as chemotherapy and radiation, by preventing cancer cells from repairing DNA damage. This leads to increased cell death in tumor cells, especially in those with p53 deficiencies, making them more vulnerable to treatment. It is studied in combination with agents like gemcitabine and irinotecan in various solid tumors and hematologic malignancies. Its role in synthetic lethality strategies highlights its potential in targeted cancer therapies.